Rv0005: gyrBRv0006: gyrA

Rv0006

More about Rv0006 on    TBDB.org

More about Rv0006 on    TubercuList

Return to gene list

Display all mutations or select a bar from the histogram above to examine in greater detail

Display high confidence mutations only
Rv0006: all mutations (high confidence mutations are highlighted in yellow)
Primary reference Polymorphism Nucleotide position Codon position Amino acid Time period Origin Molecular detection method Gene coverage Resistance pattern MIC Susceptibility testing method R/Total isolates R/S isolates with mutation Additional mutations High confidence support
Shi R JCM 2006 GCC/TCC 220 74 Ala/Ser 2002-2003 China Sequencing 227bp QRDR gyrA OFX OFL 2-32 Absolute concentration method 87/109 10/0 gyrA: Asp94Gly
Aubry A AAC 2006 ACC/GCC 238 80 Thr/Ala Published 2006 France Sequencing QRDRs on gyrA and gyrB The Thr80Ala mutants are resistant to all 5 drugs. The Thr80Ala + Ala90Gly double mutants are hypersusceptible to all 5 drugs, with MICs significantly lowered compared to H37Rv. - Proportion method 14/15 Single mutants: 2/0. Double mutants: 0/4. gyrA: Ala90Val -
Matrat S AAC 2006 Dec GGC/GCC 263 88 Gly/Ala Published 2006 N.S. Sequencing nt 247-282 of gyrA "Resistant to: sparfloxacin, gemifloxacin, gatifloxacin, moxifloxacin, levofloxacin, ofloxacin, enoxacin, temafloxacin, flumequine, oxolinic acid, nalidixic acid, pipemidic acid; and to coumarin. " 2x to 16x higher than WT (H37Rv) MICs for the same drugs. Proportion method 39938 5/0 N.S. -
Von Groll A AAC 2009 GAC/AAC 265 89 Asp/Asn Published 2006 N.S. Sequencing nt 247-282 of gyrA "Resistant to: sparfloxacin, gemifloxacin, gatifloxacin, moxifloxacin, levofloxacin, ofloxacin, enoxacin, temafloxacin, flumequine, oxolinic acid, nalidixic acid, pipemidic acid; and to coumarin. " 2x to 16x higher than WT (H37Rv) MICs for the same drugs. Proportion method 39938 5/0 N.S. -
Takiff HE AAC 1994 GCG/GTG 269 90 Ala/Val Published 1994 N.S. PCR-SSCP, Sequencing 320-bp QRDR of gyrA CIP CIP: 4-8 BACTEC 460 3/54 3/0 gyrA: Ser95Thr
Aubry A AAC 2006 GCG/GGG 269 90 Ala/Gly Published 2006 France Sequencing QRDRs on gyrA and gyrB Hypersusceptible to all 5 drugs, with MICs significantly lowered compared to H37Rv. GAT 0.12-0.5, MOX 0.12-0.25, LVX 0.25-1, OFX 0.25-1, and ENX 2-8 ug/ml. Proportion method 14/15 0/4 gyrA: Thr80Ala -
Takiff HE AAC 1994 TCG/CCG 271 91 Ser/Pro Published 1994 N.S. PCR-SSCP, Sequencing 320-bp QRDR of gyrA CIP CIP: 4 BACTEC 460 1/54 1/0 gyrA: Ser95Thr
Takiff HE AAC 1994 GAC/AAC 280 94 Asp/Asn Published 1994 N.S. PCR-SSCP, Sequencing 320-bp QRDR of gyrA CIP CIP: 8 BACTEC 460 1/54 1/0 gyrA: Ser95Thr
Takiff HE AAC 1994 GAC/CAC 280 94 Asp/His Published 1994 N.S. PCR-SSCP, Sequencing 320-bp QRDR of gyrA CIP CIP: 4 BACTEC 460 1/54 1/0 gyrA: Ser95Thr
Bravao LTC JCM 2009 GAC/GTC 280-281 94 Asp/Phe Published 2009 Phillipines Sequencing 225-bp gyrA QRDR HROfx N.S. Proportion method 9/102 1/0 gyrA: Ser95Thr -
Takiff HE AAC 1994 GAC/TAC 280 94 Asp/Tyr Published 1994 N.S. PCR-SSCP, Sequencing 320-bp QRDR of gyrA CIP CIP: 8 BACTEC 460 2/54 2/0 gyrA: Ser95Thr
Takiff HE AAC 1994 GAC/GGC 281 94 Asp/Gly Published 1994 N.S. PCR-SSCP, Sequencing 320-bp QRDR of gyrA CIP CIP: 8 BACTEC 460 5/54 5/0 gyrA: Ser95Thr
Takiff HE AAC 1994 GAC/GCC 281 94 Asp/Ala Published 1994 N.S. PCR-SSCP, Sequencing 320-bp QRDR of gyrA CIP CIP: 4 BACTEC 460 1/54 1/0 gyrA: Ser95Thr
Sulochana S J Chemother 2007 GAC/GTC 281 94 Asp/Val Published 2007 India Sequencing 320-bp gyrA QRDR, 360-bp gyrB QRDR Moderately resistant to OFX. OFX: 16-64 Absolute concentration method 71/118 7/0 gyrA: Ser95Thr -
Kapur V Arch PathLabMEd 1995 AGC/ACC 284 95 Ser/Thr - - - - - - - - - - -
Kam KM Microb Drug Res 2006 CCC/CAC 305 102 Pro/His - - - - - - - - - -
Sulochana S J Chemother 2007 CTG/GTG 325 109 Leu/Val Published 2007 India Sequencing 320-bp gyrA QRDR, 360-bp gyrB QRDR Moderately susceptible to OFX. OFX: 2 Absolute concentration method 71/118 0/1 - -

Disclaimer: These are all putative mutations found in drug resistant clinical TB isolates. No a priori decisions have been made as to whether these mutations are causally related to resistance or possible secondary mutations.

© 2010 Andreas Sandgren  |  Supported by the Swedish Research Council  |  Contact Database Curator